Categories: BioTechHealthTechLife
Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2024 | Series A | $65M | - |
Mentions in press and media 4
| Date | Title | Description |
| 24.05.2024 | The Week’s 10 Biggest Funding Rounds: Scale AI’s Massive $1B Deal Leads Slower Week | 9 Shares Email Facebook Twitter LinkedIn
Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board.
This is a w... |
| 21.05.2024 | Forbion leads $65 million Series A Financing of Progentos Therapeutics | • Forbion led the Series A financing to support the development of Progentos’ lead program in multiple sclerosis along with additional pipeline programs
• Progentos Therapeutics is developing novel small molecules to induce de-novo remyelin... |
| 20.05.2024 | Progentos Therapeutics Closes $65M Series A Financing | Progentos Therapeutics, a Watertown, MA-based biotech company addressing the need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, closed a $65m series A funding round.
Th... |
| - | Progentos Therapeutics | “Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.” |
Reviews 0
